Zim Laboratories Limited (ZIMLAB) - Total Liabilities
Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has total liabilities worth Rs2.19 Billion INR (≈ $23.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zim Laboratories Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Zim Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. See ZIMLAB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Zim Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Zim Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LiveOne Inc
NASDAQ:LVO
|
USA | $62.80 Million |
|
Samsung Climat
KO:006660
|
Korea | ₩45.28 Billion |
|
Ittifak Holding A.S.
IS:LRSHO
|
Turkey | TL9.13 Billion |
|
Genie Music Corporation
KQ:043610
|
Korea | ₩115.36 Billion |
|
PTL Enterprises Limited
NSE:PTL
|
India | Rs2.26 Billion |
|
Quantum X Labs Inc.
NASDAQ:QXL
|
USA | $6.02 Million |
|
Safety Shot Inc
NASDAQ:SHOT
|
USA | $18.98 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Zim Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zim Laboratories Limited (ZIMLAB) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zim Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zim Laboratories Limited (2013–2025)
The table below shows the annual total liabilities of Zim Laboratories Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs2.20 Billion ≈ $23.77 Million |
+5.63% |
| 2024-03-31 | Rs2.08 Billion ≈ $22.50 Million |
+47.33% |
| 2023-03-31 | Rs1.41 Billion ≈ $15.27 Million |
-14.88% |
| 2022-03-31 | Rs1.66 Billion ≈ $17.94 Million |
+1.15% |
| 2021-03-31 | Rs1.64 Billion ≈ $17.74 Million |
-4.34% |
| 2020-03-31 | Rs1.71 Billion ≈ $18.55 Million |
-3.30% |
| 2019-03-31 | Rs1.77 Billion ≈ $19.18 Million |
+9.68% |
| 2018-03-31 | Rs1.62 Billion ≈ $17.49 Million |
+14.89% |
| 2017-03-31 | Rs1.41 Billion ≈ $15.22 Million |
-10.83% |
| 2016-03-31 | Rs1.58 Billion ≈ $17.07 Million |
-7.66% |
| 2015-03-31 | Rs1.71 Billion ≈ $18.48 Million |
+15.82% |
| 2014-03-31 | Rs1.48 Billion ≈ $15.96 Million |
+32.34% |
| 2013-03-31 | Rs1.11 Billion ≈ $12.06 Million |
-- |
About Zim Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more